Utility of total lymphocyte count as a surrogate marker for CD4 counts in HIV-1 infected children in Kenya

详细信息    查看全文

• 作者：Nyawira Githinji (1)
  Elizabeth Maleche-Obimbo (1)
  Moses Nderitu (2)
  Dalton C Wamalwa (1)
  Dorothy Mbori-Ngacha (1)
  
• 关键词：Total Lymphocyte Count ; TLC ; CD4 ; HIV ; Children ; surrogate marker
• 刊名：BMC Infectious Diseases
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：11
• 期：1
• 全文大小：163KB
• 参考文献：1. Kenya Demographic Health Survey Central Bureau of Statistics, Nairobi; 2003:89-1.
  2. Kenya AIDS Indicator Survey National AIDS Control Program Ministry of health Kenya; 2007.
  3. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, Richardson BA, Otieno PA, Bosire R, Farquhar C, Overbaugh J, John-Stewart GC: Predictors of Early Mortality in a Cohort of Human Immunodeficiency Virus Type-1 - Infected African Children. / Pediatr Infect Dis J 2004,23(6):536-43. CrossRef
  4. Spira R, Lepage P, Msellati P, Van de Perre P, Leroy V, Simonon A, Karita E, Davis F: Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. / Pediatrics 1999,104(5):e56. CrossRef
  5. Tahaa TE, Kumwenda NI, Broadhead RL, Hoover DR, Graham SM, Van Der Hoven L, Markakis D, Liomba GN, Chiphangwi JD, Miotti PG: Mortality after the first year of life among Human Immunodeficiency Virus type 1-infected and uninfected children. / Pediatr Infect Dis J 1999,18(8):689-4. CrossRef
  6. Mbori-Ngacha D, Nduati R, John G, Reilly M, Richardson B, Mwatha A, Ndinya-Achola J, Bwayo J, Kreiss J: Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: a randomized clinical trial. / JAMA 2001, 286:2413-420. CrossRef
  7. Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA, Richardson BA, Overbaugh J, Emery S, Wariua G, Gichuhi C, Bosire R, John-Stewart G: Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. / J Acquir Immune Defic Syndr 2007,45(3):311-.
  8. Nyandiko WM, Ayaya S, Nabakwe E, Tenge C, Sidle JE, Yiannoutsos CT, Musick B, Wools-Kaloustian K, Tierney WM: Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. / J Acqir Immune Defic Syndr 2006,43(4):418-5. CrossRef
  9. Reddi A, Leeper SC: Antiretroviral therapy adherence in children: outcomes from Africa. / AIDS 2008,22(7):906-. CrossRef
  10. Van Winghem J, Telfer B, Reid T, Ouko J, Mutinga A, Jama Z, Vakil S: Implementation of a comprehensive program including psycho-social and treatment literacy activities to improve adherence to HIV care and treatment for a pediatric population in Kenya. / BMC Pediatr 2008, 8:52. CrossRef
  11. Dunn D: Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta analysis. / Lancet 2003,362(9396):1605-1. CrossRef
  12. HIV Pediatric Prognostic Markers Collaborative Study: Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. / AIDS 2006,20(9):1289-4. CrossRef
  13. Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K, HIV Pediatric Prognostic Markers Collaborative Study (HPPMCS), Concerted Action on Sero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration: Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. / J Infect Dis 2008,197(3):398-04. CrossRef
  14. World Health Organization: Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. / Recommendations for a public health approach 2006.
  15. Beck EJ, Kupek EJ, Gompels MM, Pinching AJ: Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect. / Int J STD AIDS 1996, 6:422-. CrossRef
  16. Spacek LA, Griswold M, Quinn TC, Moore RD: TLC and hemoglobin combined in an algorithm to initiate the use of HAART in resource limited settings. / J AIDS 2003, 17:1311-317. CrossRef
  17. Kumarasamy N, Mahajan AP, Flamigan TP, Hemalatha R, Mayer KH, Carpenter CC, Thyagarajan SP, Solomon S: TLC is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource constrained settings. / J Acquir Immune Defic Sndr 2002, 31:378-3. CrossRef
  18. Gitura BM, Joshi MD, Lule GN, Anzala O: Total Lymphocyte Count as a surrogate marker for CD4+ T cells count in initiating HAART at Kenyatta National Hospital, Nairobi. / East African Medical Journ 2007, 84:466-72.
  19. Kamya MR, Semitala FC: TLC of 1200 is not a sensitive predictor of CD4 Lymphocyte count among patients with HIV disease in Kampala, Uganda. / Afr Health Science 2004, 2:941-01.
  20. Spitalnic S: Test properties 1: Sensitivity, Specificity and predictive values Hospital Physician. [http://www.turner-white.com] 2004, 1:27-1.
  21. Dunn DT, Gibb DM, Duong T, Babiker AG, / et al.: Use of TLC for informing when to start ART in HIV infected children. / Lancet 2005, 366:1868-4. CrossRef
  22. The President's Emergency Plan For AIDS Relief, (PEPFAR), Next Generation Indicators Reference Guide [http://www.pepfar.gov]
  23. Flanigan TP, Mahajan AP, Kumarasamy N: TLC as a surrogate for CD4 count to initiate and monitor HAART in resource limited countries. / 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002
  24. Musoke PM, Young AM, Owor M, Lubega IR, Brown ER, Mmiro FA, Mofenson LM, Jackson JB, Fowler MG, Guay LA: Total Lymphocyte Count: Not a surrogate marker for risk of death in HIV infected Ugandan children. / J Acquir Immune Defic Syndr 2008, 49:171-78. CrossRef
  25. Kiepiela P, Coovadia HM, Coward P, Woodhead R, Abdool-Karim SS, Becker P: Age-related lymphocyte sub-population changes among health African from birth to adulthood. / Ann Trop Pedtr 1989, 9:199-05.
  26. Mahajan AP, Hogan JW, Snyder B, Kumarasamy N, Mehta K, Solomon S, Carpenter CC, Mayer KH, Flanigan TP: Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. / J Acquir Immune Defic Syndr 2004,36(1):567-5. CrossRef
  27. Bolton-Moore C, Mubiana-Mbewe M, Cantrell J, Chintu N, Stringer EM, Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, Mwango A, Levy J, Abrams EJ, Bulterys M, Stringer JS: Clinical outcomes and CD4 response in children receiving antiretroviral therapy at primary health care facilities in Zambia. / JAMA 2007,298(16):1888-899. CrossRef
  28. Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Viok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J: Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. / BMC Pediatr 2007, 7:7-3. CrossRef
  29. Martin DJ, Sim JG, Sole GJ, Rymer L, Shalekoff S, van Niekerk AB, Becker P, Weilbach CN, Iwanik J, Keddy K, / et al.: CD4+ lymphocyte count in African patients co-infected with HIV and tuberculosis. / J Acquir Immune Defic Syndr Hum Retrovirol 1995,8(4):386-1.
  30. DART Trial team: Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial. / Lancet 2010, 375:123-1. CrossRef
  31. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/11/259/prepub
  
• 作者单位：Nyawira Githinji (1)
  Elizabeth Maleche-Obimbo (1)
  Moses Nderitu (2)
  Dalton C Wamalwa (1)
  Dorothy Mbori-Ngacha (1)
  
  1. Department of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya
  2. Kenya Medical Research Institute-Wellcome Trust Research Program, Nairobi, Kenya
  

文摘

Background In resource-limited settings, such as Kenya, access to CD4 testing is limited. Therefore, evaluation of less expensive laboratory diagnostics is urgently needed to diagnose immuno-suppression in children. Objectives To evaluate utility of total lymphocyte count (TLC) as surrogate marker for CD4 count in HIV-infected children. Methods This was a hospital based retrospective study conducted in three HIV clinics in Kisumu and Nairobi in Kenya. TLC, CD4 count and CD4 percent data were abstracted from hospital records of 487 antiretroviral-na?ve HIV-infected children aged 1 month - 12 years. Results TLC and CD4 count were positively correlated (r = 0.66, p < 0.001) with highest correlation seen in children with severe immuno-suppression (r = 0.72, p < 0.001) and children >59 months of age (r = 0.68, p < 0.001). Children were considered to have severe immuno-suppression if they met the following WHO set CD4 count thresholds: age below 12 months (CD4 counts < 1500 cells/mm3), age 12-35 months (CD4 count < 750 cells/mm3), age 36-59 months (CD4 count < 350 cells/mm3, and age above 59 months (CD4 count < 200 cells/mm3). WHO recommended TLC threshold values for severe immuno-suppression of 4000, 3000, 2500 and 2000 cells/mm3 for age categories <12, 12-35, 36-59 and >59 months had low sensitivity of 25%, 23%, 33% and 62% respectively in predicting severe immuno-suppression using CD4 count as gold standard. Raising TLC thresholds to 7000, 6000, 4500 and 3000 cells/mm3 for each of the stated age categories increased sensitivity to 71%, 64%, 56% and 86%, with positive predictive values of 85%, 61%, 37%, 68% respectively but reduced specificity to 73%, 62%, 54% and 68% with negative predictive values of 54%, 65%, 71% and 87% respectively. Conclusion TLC is positively correlated with absolute CD4 count in children but current WHO age-specific thresholds had low sensitivity to identify severely immunosuppressed Kenyan children. Sensitivity and therefore utility of TLC to identify immuno-suppressed children may be improved by raising the TLC cut off levels across the various age categories.